

Product Data Sheet

Product Name: Talogreptide vizaxetan

Cat. No.: GC79280

Chemical Properties

Cas. No. 1186600-65-6


Formula $C_{78}H_{118}N_{20}O_{19}$ M.Wt 1639.89

Solubility DMSO: 100 mg/mL (60.98 mM; Need Storage Sealed storage, away from moisture ultrasonic)

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

RM2 is a GRPr antagonist. RM2 selectively binds to GRPr, blocks agonist-induced receptor internalization, and inhibits agonist-triggered intracellular calcium mobilization. RM2 can be used in studies related to prostate cancer [1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

In Vivo, ¹¹¹In-RM2 (10 pmol; intravenous tail vein injection) achieves high, sustained, GRPr-specific uptake in PC-3 prostate cancer xenografts, with tumour to blood ratios reaching 4070 at 72 hours post-injection^[1]. ⁶⁸Ga-RM2 (80 pmol; intravenous injection) exhibits high, GRPr-specific uptake in PC-3 prostate cancer xenografts, with tumour to kidney ratios reaching 6.1 at 80 minutes post-injection^[1]. ⁶⁸Ga-RM2 (80 pmol; intravenous injection) achieves specific, GRPr-mediated uptake in androgen-dependent LNCaP prostate cancer xenografts, with tumour to blood ratios reaching 23.4 at 120 minutes post-injection^[1].

In Vitro, RM2 binds the GRP receptor on human prostate carcinoma cryostat sections with high affinity, exhibiting an IC₅₀ of 7.7nmol/L^[1]. RM2 is a selective ligand for the GRP receptor on human tissue sections, with an IC₅₀ of 9.3 nmol/L and no measurable affinity for NMBr or BB3r subtypes^[1]. RM2 (1000 nmol/L; 30 min) acts as a GRP receptor antagonist in HEK-GRPr cells, failing to trigger receptor internalization at 1000 nmol/L but completely inhibiting Bombesin -induced receptor internalization at the same concentration^[1]. RM2 (1-10 µmol/L; 60 s) acts as a GRP receptor antagonist in PC-3 cells, showing no intrinsic activity on intracellular Ca²⁺ mobilization at 1 or 10 µmol/L, but inhibiting Bombesin -induced Ca²⁺ mobilization at 10 µmol/L^[1].

References:

[1]. Mansi R, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38(1):97-107.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA